Ipamorelin 10 mg (≥99% Purity) — Research Use Only
Specifications
| Chemical Name | Ipamorelin (NNC 26-0161) |
| Sequence | H-Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| CAS Number | 170851-70-4 |
| PubChem CID | CID 9831659 |
| Molecular Formula | C38H49N9O5 |
| Molecular Weight (avg.) | ≈ 711.85 g/mol |
| Monoisotopic Mass | ≈ 711.39 Da |
| Physical Appearance | White to off-white lyophilized powder |
| Container | 3 mL Type I glass vial (10 mg net content) |
| Purity | ≥ 99% (verified by HPLC & MS; 3rd-party tested) |
| Solubility | Soluble in sterile water or compatible buffer; for difficult matrices, pre-wet with ≤0.1% acetic acid or minimal DMSO, then bring to final buffer. 0.22 µm filter-sterilize if required. |
Molecular Structure
Why Peptide Tech
- Same-Day Shipping
- GMP-Aligned Lyophilized Peptides
- USA Made
- 24/7 Support
- Price Match Guarantee
- Batch Tracking with QR Code Verification
- 3rd-Party USA Lab Testing — purity, quantity, endotoxin
- Cold-Chain Shipping — Always (no paid upgrade)
- Worldwide Shipping
- All Major Payments Accepted
- Text & Email Order Updates
- 2-Day FedEx/UPS Shipping Standard
- Cheapest Overnight Rates
- Largest Variety of Peptides & Bioregulators
Storage & Handling
- Lyophilized (unopened): Store at ≤ −20 °C, desiccated and protected from light. For long-term archival, ≤ −80 °C is recommended.
- After reconstitution: Aliquot into sterile, low-binding tubes; store at ≤ −80 °C. Avoid repeated freeze–thaw cycles.
- Handling: Allow vial to reach room temperature before opening to minimize condensation. Use sterile technique and neutral pH buffers; add carrier protein (e.g., 0.1% BSA) if adsorption is a concern.
- Research Use Only (RUO): Not for human or veterinary use, ingestion, diagnostic, or therapeutic applications.
Potential Applications in Research
Strictly in-vitro, cellular, or biochemical contexts — no clinical or human-use claims.
- GHS-R1a receptor pharmacology & selectivity: Compare Ipamorelin’s selective GH secretagogue activity vs. other GHRPs in pituitary cell assays.
Raun et al., 1998. - Pituitary GH release models: Quantify dose-response (EC50, Emax) for GH secretion in primary pituitary cultures.
Raun et al., 1998. - PK/PD method development: Use controlled infusion/exposure data to build compartmental models and exposure–response relationships for secretagogue activity.
Gobburu et al., 1999. - GI motility pathways (preclinical): Explore ghrelin-receptor–mediated effects on gastric contractility and transit in rodent surgical models (mechanistic endpoints only).
Greenwood-Van Meerveld et al., 2012.
Citations (PubMed)
- Raun, K., et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology, 1998;139(5):552–561.
PMID: 9849822 - Gobburu, J.V.S., Agersø, H., Jusko, W.J., Ynddal, L. “Pharmacokinetic–pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.” Pharmaceutical Research, 1999;16(9):1412–1416.
PMID: 10496658 - Greenwood-Van Meerveld, B., Tyler, K., Mohammadi, E., Pietra, C. “Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.” Journal of Experimental Pharmacology, 2012;4:149–155.
PMID: 27186127
Compliance & RUO Disclaimer
For laboratory research use only (RUO). Not a drug, food, or cosmetic. Not for human or veterinary use. Purchase and use are limited to qualified personnel operating under institutional laboratory guidelines.
Related Products
Browse more in Peptides.
Always read the label and use products as directed. Consult a qualified professional where appropriate.









